Clinical trials: Apathy, open to volunteers
Apathy, Apathy in Dementia
Robotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel)
The goal of this trial is to learn whether home-based robotic interventions can reduce apathy in people with cognitive decline. Apathy means reduced motivation, interest, or initiative in daily life.
- Trial name
- RAPHAel (NCT07404410)
- Testing
- telepresence robotic system, Pepper robot connected to a CAIR server, Occupational Therapy
- Where
- 2 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Giovanna Zamboni
Huntington Disease
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
The goal of this observational study is to learn about the usefulness of a test of social functioning in persons with Huntington disease.
- Trial name
- NCT07253038
- Where
- Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Region Skane
Apathy in Dementia
The Volunteering-in-Place Program for Apathetic Assisted Living Residents With ADRD
This is a research study to test two different interventions to decrease apathy in assisted living residents with some memory issues. Apathy makes older adults not feel like doing much activity.
- Trial name
- NCT06735950
- Testing
- Volunteering in Place Program, Recreational activity
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Maryland, Baltimore
Apathy
In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy.
Apathy is a neurocognitive syndrome characterized by reduced goal-directed behaviors, contributing to decreased patient and caregiver quality of life.
- Trial name
- ADACHOL (NCT03998852)
- Testing
- Positron Emission Tomography (PET) with [18F]-FDOPA, Positron Emission Tomography (PET) with [18F]-FEOBV, Magnetic Resonnance Imaging (MRI)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
Apathy
Multidimensional Apathy in Psychiatric Pathologies.
Apathy is defined by quantitative decrease in goal-directed activity in comparison to the person's previous level of functioning.
- Trial name
- AmSeD (NCT04757220)
- Testing
- Cognitive tasks with EEG recording
- Where
- France
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Parkinson Disease, Deep Brain Stimulation
VC/VS for Apathy in PD
Apathy is a disabling neuropsychiatric symptom marked by reduced goal-directed behavior, including diminished interest, motivation, emotional expression, and social engagement.
- Conditions
- Parkinson Disease, Deep Brain Stimulation, Apathy
- Trial name
- NCT06991335
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nora Vanegas
Schizo-affective Disorder, Non Organic Psychosis
Motivational Intervention for Patients With Schizophrenia
The goal of this clinical trial is to learn if a group therapy called the Positive Emotions Program for Schizophrenia (PEPS) can reduce apathy in adults aged 18 to 60 who have schizophrenia or a related psychotic disorder.
- Conditions
- Schizo-affective Disorder, Non Organic Psychosis, Schizophenia Disorder
- Trial name
- NCT07853079
- Testing
- Positive Emotion Program for Schizophrenia (PEPS), a psychotherapeutic intervention,
- Volunteers
- 88 people
- Sponsor
- University of Geneva, Switzerland
Parkinson Disease
Apathy in Parkinson Disease TMS Study
The goal of this clinical trial is to develop non-invasive brain stimulation targets for the treatment of apathy, or motivation problems, in Parkinson Disease. The main questions the study aims to answer are: 1.
- Trial name
- PDTMSAPATHY (NCT06087926)
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Persistent Negative Symptoms
Stratifying Psychoses for Personalized REpetitive TMS in Persistent NEgative Symptoms Alleviation
In its 2012's release guideline on therapy for schizophrenia, the EMA joined the FDA to acknowledge primary and persistent negative symptoms (PNS) as an unmet need in the treatment of schizophrenia.
- Conditions
- Schizophrenia, Persistent Negative Symptoms, Progressive Periodic Catatonia, Aviation
- Trial name
- SP-RENESA (NCT06184165)
- Testing
- Personalized rTMS
- Volunteers
- 160 people
- Sponsor
- University Hospital, Strasbourg, France